Symposia & Webinars
Strictly following the Guidelines is the Key to Reaching Targets
The comprehensive presentation with Neil Poulter starts with drug choice and sequencing in ISH 2020 and the recommended 2-drug combinations of antihypertensive drugs in the guidelines.
He continues with A&C trials and A+D Trials trying to find an answer for which is the optimal combination.
Afterwards he goes back to the individual drug classes:
- A (ACE-I or ARB)
- Difference between ACE inhibitors and ARBs on mortality reductions in recent meta-analyses
- ARBs missing or fail where ACE-I succeeded
- D (Thiazide-like duretic)
- Indapamide is superior to HCTZ for BP reduction
- Efficacy of diuretics in the hypertension trial (summary)
- C (DHP Calcium Channel Blocker)
The presentation also addresses:
- Guidelines recommendation about triple therapy
- Advantages of Fix Dose combinations (FDC)/Single pill combinations (SPC)
- Efficacy of SPC vs high dose monotherapy
- Adherence FDC and compliance ratio’s
- Initial combination therapy vs initial monotherapy; impact on CV outcomes in Large Case-Control Study
- Summary of benefits of single pill combinations
This video is part of the session “Single-pill combinations in the management of hypertension: evidence from new guidelines, practical benefits for both physicians and patients” held virtually at ESC Asia Virtual Congress on Friday December 4th, 2020, with chairperson N. Poulter (UK).
View also the other parts of the congress session: